Citius Oncology (NASDAQ:CTOR) Lowered to “Hold” Rating by Maxim Group

Citius Oncology (NASDAQ:CTOR) was downgraded by equities research analysts at Maxim Group from a “strong-buy” rating to a “hold” rating in a research note issued on Friday, MarketBeat reports.

Citius Oncology Price Performance

Shares of NASDAQ:CTOR opened at $0.91 on Friday. Citius Oncology has a 12-month low of $0.55 and a 12-month high of $4.42. The business has a 50 day moving average of $0.76 and a two-hundred day moving average of $1.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.34 and a quick ratio of 0.08.

Citius Oncology (NASDAQ:CTOR) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02).

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Citius Oncology stock. Citadel Advisors LLC purchased a new stake in Citius Oncology, Inc. (NASDAQ:CTOR) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 22,699 shares of the company’s stock, valued at approximately $26,000. 70.52% of the stock is owned by institutional investors and hedge funds.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.